UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Analysts

Shares of UroGen Pharma Ltd. (NASDAQ:URGN) have earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $38.20.

A number of equities analysts have issued reports on the company. LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 target price for the company. D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a research note on Monday, March 10th. Finally, HC Wainwright decreased their price target on UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th.

UroGen Pharma Price Performance

Shares of URGN opened at $12.13 on Friday. UroGen Pharma has a 12-month low of $9.03 and a 12-month high of $20.70. The business has a 50-day simple moving average of $10.54 and a two-hundred day simple moving average of $11.57. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The stock has a market cap of $559.12 million, a PE ratio of -3.85 and a beta of 1.12.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. Analysts anticipate that UroGen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the sale, the insider now owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares of the company’s stock, valued at $294,853.52. This represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in UroGen Pharma by 4.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company’s stock worth $231,000 after acquiring an additional 969 shares in the last quarter. Rhumbline Advisers boosted its holdings in UroGen Pharma by 2.8% in the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock worth $546,000 after acquiring an additional 1,402 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in UroGen Pharma by 13.6% in the fourth quarter. MetLife Investment Management LLC now owns 22,766 shares of the company’s stock worth $242,000 after acquiring an additional 2,727 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in UroGen Pharma by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock worth $996,000 after acquiring an additional 3,024 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in UroGen Pharma by 24.6% in the fourth quarter. Legal & General Group Plc now owns 19,845 shares of the company’s stock worth $211,000 after acquiring an additional 3,920 shares in the last quarter. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.